JCAR-024

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameJCAR-024
Drug Alias NameJCAR-024
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionWnt signalling pathway modulatorsInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHematologic Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterJuno Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFred Hutchinson Cancer Research CenterJuno Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHematologic Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A